Erectile dysfunction as a complication of heart failure

Current Heart Failure Reports

Volumn 7, Issue 4, 2010, Pages 194-201

  Baraghoush, Afshan ^a   Phan, Anita ^a   Willix Jr , Robert D ^b   Schwarz, Ernst R ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Cenegenics Medical Institute   (United States)

Author keywords

Cardiac function; Coronary artery disease; Depression; Erectile dysfunction; Exercise capacity; Heart failure; Medication side effects; Phosphodiesterase 5 inhibitors; Quality of life; Sexual function; Vascular dysfunction

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROCHLOROTHIAZIDE; NEBIVOLOL; PROPRANOLOL; SILDENAFIL; SPIRONOLACTONE; TADALAFIL; VALSARTAN; VARDENAFIL;

ANDROGEN THERAPY; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; EXERCISE; GYNECOMASTIA; HEART FAILURE; HEART FUNCTION; HUMAN; HYPERTENSION; LIBIDO; NONHUMAN; PENIS PROSTHESIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

CARDIOVASCULAR AGENTS; COMPREHENSIVE HEALTH CARE; ERECTILE DYSFUNCTION; HEART FAILURE; HEART FUNCTION TESTS; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS; QUALITY OF LIFE; RISK FACTORS; TREATMENT OUTCOME;

EID: 78649686509     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-010-0023-7     Document Type: Review

References (56)

1. SA Hunt WT Abraham MH Chin, et al. 2005 ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society Circulation 112 e154 e235 10.1161/CIRCULATIONAHA.105.167586 16160202
2. D Lloyd-Jones RJ Adams TM Brown, et al. 2010 Heart disease and stroke statistics 2010 updates: a report from the American Heart Association Circulation 121 e46 e215 10.1161/CIRCULATIONAHA.109.192667 20019324 Published erratum appears in Circulation 2010, 121:e260
3. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993, 270:83-90.
4. I Goldstein 2000 The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction Am J Cardiol 86 41F 45F 1:STN:280:DC%2BD3czpvFKhsw%3D%3D 10.1016/S0002-9149(00)00892-4 10899278
5. KK Chew A Bremner B Stuckey, et al. 2009 Sex life after 65: how does erectile dysfunction affect ageing and elderly men? Aging Male 12 41 46 10.1080/13685530802273400 19378217
6. ER Schwarz S Rastogi V Kapur, et al. 2006 Erectile dysfunction in heart failure patients J Am Coll Cardiol 48 1111 1119 10.1016/j.jacc.2006.05.052 16978992 (Pubitemid 44363150)
7. S Rastogi JJ Rodriguez V Kapur ER Schwarz 2005 Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach this problem Int J Impot Res 17 Suppl 1 S25 S36 10.1038/sj.ijir.3901426 16391540 (Pubitemid 43049374)
8. KK Chew A Bremner K Jamrozik, et al. 2008 Male erectile dysfunction and cardiovascular disease: is there an intimate nexus? J Sex Med 5 928 934 10.1111/j.1743-6109.2007.00714.x 18194189 (Pubitemid 351478237)
9. J Meluzín A Vasků V Kincl, et al. 2009 Association of coronary artery disease, erectile dysfunction, and endothelial nitric oxide synthase polymorphisms Heart Vessels 24 157 163 10.1007/s00380-008-1097-y 19466514
10. IM Thompson CM Tangen PJ Goodman, et al. 2005 Erectile dysfunction and subsequent cardiovascular disease JAMA 294 2996 3002 1:CAS:528: DC%2BD2MXhtleltLrK 10.1001/jama.294.23.2996 16414947 (Pubitemid 41817661)
11. A Ponholzer G Gutjahr C Temml S Madersbacher 2010 Is erectile dysfunction a predictor of cardiovascular events or stroke? A prospective study using a validated questionnaire Int J Imp Res 22 25 29 1:STN:280: DC%2BC3c%2FhvFygsQ%3D%3D 10.1038/ijir.2009.40
12. ED Nemec L Mansfield JW Kennedy 1976 Heart rate and blood pressure responses during sexual activity in normal males Am Heart J 92 274 277 1:STN:280:DyaE283ltVSrsg%3D%3D 10.1016/S0002-8703(76)80106-8 949020
13. JG Bohlen JP Held MO Sanderson RP Patterson 1984 Heart rate, rate-pressure product, and oxygen uptake during four sexual activities Arch Intern Med 144 1745 1748 1:STN:280:DyaL2czgs1amtg%3D%3D 10.1001/archinte.144.9. 1745 6476990 (Pubitemid 14070024)
14. B Cremers B Kjellström M Südkamp M Böhm 2002 Hemodynamic monitoring during sexual intercourse and physical exercise in a patient with chronic heart failure and pulmonary hypertension Am J Med 112 428 430 10.1016/S0002-9343(01)01119-6 11904125 (Pubitemid 34246280)
15. T Jaarsma K Dracup J Walden LW Stevenson 1996 Sexual function in patients with advanced heart failure Heart Lung 25 262 270 1:STN:280: DyaK28vjtlOlsA%3D%3D 10.1016/S0147-9563(96)80061-6 8836742 (Pubitemid 26285023)
16. A Apostolo C Vignati D Brusoni, et al. 2009 Erectile dysfunction in heart failure: correlation with severity, exercise performance, comorbidities, and heart failure treatment J Sex Med 6 2795 2805 1:CAS:528:DC%2BD1MXhtlKqtL7J 10.1111/j.1743-6109.2009.01416.x 19674255
17. TF Lue 2000 Erectile dysfunction N Engl J Med 342 1802 1813 1:CAS:528:DC%2BD3cXksVequ7c%3D 10.1056/NEJM200006153422407 10853004 (Pubitemid 30390241)
18. RA Kloner 2004 Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction Circulation 110 3149 3155 10.1161/01.CIR.0000146906.42375.D3 15533876 (Pubitemid 39492012)
19. RH Boger SM Bode-Boger JC Frolich 1996 The L-arginine-nitric oxide pathway: role in atherosclerosis and therapeutic implications Atherosclerosis 127 1 11 1:STN:280:DyaK2s7lvFCmuw%3D%3D 10.1016/S0021-9150(96)05953-9 9006798 (Pubitemid 26425836)
20. O Yavuzgil B Altay M Zoghi, et al. 2005 Endothelial function in patients with vasculogenic erectile dysfunction Int J Cardiol 103 19 26 10.1016/j.ijcard.2004.07.004 16061118 (Pubitemid 41074599)
21. CJ Smith D Sun C Hoegler, et al. 1996 Reduced gene expression of vascular endothelium NO synthase and cyclooxygenase-1 in heart failure Circ Res 78 58 64 1:CAS:528:DyaK28XltVKr 8603506
22. C Vlachopoulos K Aznaouridis N Ioakeimidis, et al. 2006 Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease Eur Heart J 27 2640 2648 1:CAS:528: DC%2BD28XhtlCmtbjJ 10.1093/eurheartj/ehl341 17056702 (Pubitemid 44729862)
23. AJ Becker S Uckert CG Steif, et al. 2001 Systemic and cavernosal plasma levels of endothelin (1-21) during different penile conditions in healthy males and patients with erectile dysfunction World J Urol 19 371 376 1:CAS:528:DC%2BD38XjvVygtA%3D%3D 10.1007/s003450100213 11760787 Published erratum appears in World J Urol 2002, 19:462 (Pubitemid 33777084)
24. CA Pedersen ML Boccia 2006 Vasopressin interactions with oxytocin in the control of female sexual behavior Neuroscience 139 843 851 1:CAS:528: DC%2BD28XktVygt7g%3D 10.1016/j.neuroscience.2006.01.002 16488546
25. A Neri Z Zukerman M Aygen, et al. 1987 The effect of long-term administration of digoxin on plasma androgens and sexual dysfunction J Sex Marital Ther 13 58 63 1:STN:280:DyaL2s7pvVOhtQ%3D%3D 2952803
26. S Gupta P Salimpour I Saenz de Tejada, et al. 1998 A possible mechanism for alteration of human erectile function by digoxin: inhibition of corpus cavernosum sodium/potassium adenosine triphosphate activity J Urol 159 1529 1536 1:CAS:528:DyaK1cXms1CjsL4%3D 10.1097/00005392-199805000-00033 9554348
27. S Wassertheil-Smoller MD Blaufox A Oberman, et al. 1991 Effect of antihypertensives on sexual function and quality of life: the TAIM study Ann Intern Med 114 613 620 1:STN:280:DyaK3M7ms1Wlsw%3D%3D 2003706
28. J Ménard 2004 The 45-year story of the development of an anti-aldosterone more specific than spironolactone Mol Cell Endocrinol 217 45 52 10.1016/j.mce.2003.10.008 15134800 (Pubitemid 38596628)
29. R Fogari A Zoppi L Poletti, et al. 2001 Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study Am J Hypertens 14 27 31 1:CAS:528:DC%2BD3MXhsFajs7o%3D 10.1016/S0895-7061(00)01214-0 11206674 (Pubitemid 32105914)
30. A Silvestri P Galleta E Cerquetani, et al. 2003 Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of the side effects and is reversed by placebo Eur Heart J 24 1928 1932 1:CAS:528:DC%2BD3sXosVygtbo%3D 10.1016/j.ehj.2003.08.016 14585251 (Pubitemid 37322702)
31. A Cordero V Bertomeu-Martínez P Mazón, et al. 2010 Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents Cardiovasc Ther 28 15 22 1:CAS:528:DC%2BC3cXitlWit7k%3D 10.1111/j.1755-5922.2009.00123.x 20074255 This article covers a cross-sectional and observational study of men with hypertension treated with β-blockage agents for at least 6 months. They found that patients treated with nebivolol versus other agents obtained higher scores on every parameter on the International Index of Erectile Function questionnaire and the odds ratio for development of ED was 0.27
32. Angulo J, Wright HM, Cuevas P, et al.: Nebivolol dilates human penile arteries and reverses erectile dysfunction in diabetic rats through enhancement of nitric oxide signaling. J Sex Med 2010 Feb 25 (Epub ahead of print).
33. R DiBianco 1991 A large-scale trial of captopril for mild to moderate heart failure in the primary care setting Clin Cardiol 14 676 682 1:STN:280:DyaK38%2Fgs1ehsw%3D%3D 10.1002/clc.4960140810 1914272
34. R Dusing 2003 Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men Blood Press Suppl 2 29 34 1:STN:280: DC%2BD2c%2FmtVWgtg%3D%3D 10.1080/08038020310021967 14761074
35. O Canguven G Lagoda SF Sezen AL Burnett 2009 Losartan preserves erectile function after bilateral cavernous nerve injury via antifibrotic mechanisms in male rats J Urol 181 2816 2822 1:CAS:528:DC%2BD1MXmtV2isbo%3D 10.1016/j.juro.2009.01.097 19375729 This study offers a proposed mechanism of improved erectile function in rats treated with losartan. The authors found losartan to affect the levels of fibronectin, pSMAD2, thrombospondin-1, and SMAD2, with a consequent decrease in penile fibrosis and ED
36. M Böhm M Baumhäkel K Teo, et al. 2010 Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials Circulation 121 1439 1446 10.1161/CIRCULATIONAHA.109.864199 20231536
37. S Friedman 2000 Cardiac disease, anxiety, and sexual functioning Am J Cardiol 86 46F 50F 1:STN:280:DC%2BD3czpvFKhsA%3D%3D 10.1016/S0002-9149(00)00893- 6 10899279
38. JL Hannan MT Maio M Komolova MA Adams 2009 Beneficial impact of exercise and obesity interventions on erectile function and its risk factors J Sex Med 6 254 261 10.1111/j.1743-6109.2008.01143.x 19170860 This study provides a literature review as well as a new analysis of study findings on the effects of diet and exercise on ED and cardiovascular diseases. Both diet and exercise individually were found to improve both measured outcomes with the effects of the two interventions compounded when used in conjunction
39. B Riegel DK Moser M Powell, et al. 2006 Nonpharmacologic care by heart failure experts J Card Fail 12 149 153 16520265
40. M Medina C Walker EE Steinke, et al. 2009 Sexual concerns and sexual counseling in heart failure Prog Cardiovasc Nurs 24 141 148 10.1111/j.1751-7117. 2009.00052.x 20002338
41. JB Kostis G Jackson R Rosen, et al. 2005 Sexual dysfunction and the cardiac risk (the Second Princeton Consensus Conference) Am J Cardiol 96 313 321 10.1016/j.amjcard.2005.03.065 16018863 (Pubitemid 40978596)
42. RA Kloner AM Hutter JT Emmick, et al. 2003 Time course of the interaction between tadalafil and nitrates J Am Coll Cardiol 42 1855 1860 1:CAS:528:DC%2BD3sXpvVGjsbg%3D 10.1016/j.jacc.2003.09.023 14642699 (Pubitemid 37433669)
43. LJ Webster ED Michelakis T Davis SL Archer 2004 Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial Arch Intern Med 164 514 520 1:CAS:528:DC%2BD2cXisleru7s%3D 10.1001/archinte.164.5.514 15006828 (Pubitemid 38314447)
44. D Freitas R Athanazio D Almeida, et al. 2006 Sildenafil improves quality of life in men with heart failure and erectile dysfunction Int J Impot Res 18 210 212 1:CAS:528:DC%2BD28XhvFaju7k%3D 10.1038/sj.ijir.3901385 16121207 (Pubitemid 43336491)
45. SD Katz JD Parker DB Glasser, et al. 2005 Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure Am J Cardiol 95 36 42 1:CAS:528:DC%2BD2cXhtFahs7nL 10.1016/j.amjcard.2004.08.060 15619391 (Pubitemid 40051109)
46. F Giuliano G Jackson F Montorsi, et al. 2010 Safely of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safely database Int J Clin Pract 64 240 255 1:CAS:528: DC%2BC3cXksVeqtLw%3D 10.1111/j.1742-1241.2009.02254.x 19900167 This review provides an analysis for 67 double-blind placebo-controlled trials as well as an analysis of the postmarketing database to evaluate the safety of sildenafil therapy in men in regards to cardiovascular side effects. No links were found between cardiovascular events and sildenafil use in the general population
47. K Hirata A Adji C Vlachopoulos MF O'Rourke 2005 Effect of sildenafil on cardiac performance in patients with heart failure Am J Cardiol 96 1436 1440 1:CAS:528:DC%2BD2MXht1Sru7fE 10.1016/j.amjcard.2005.06.091 16275194 (Pubitemid 41566628)
48. 2 at maximal exercise, with the effects particularly pronounced in the subset of patients with pulmonary hypertension (Pubitemid 46058612)
49. A Al-Hesayen JS Floras JD Parker 2006 The effects of intravenous sildenafil on hemodynamics and cardiac sympathetic activity in chronic human heart failure Eur J Heart Fail 8 864 868 1:CAS:528:DC%2BD28Xht1eqtbjL 10.1016/j.ejheart.2006.03.007 16829186 (Pubitemid 44794484)
50. G Piccirillo M Nocco M Lionetti, et al. 2002 Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure Am Heart J 143 703 710 1:CAS:528:DC%2BD38Xkt1CqsL8%3D 10.1067/mhj.2002.121547 11923809 (Pubitemid 34454705)
51. A Behling LE Rohde FC Colombo, et al. 2008 Effects of 5-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial J Card Fail 14 189 197 1:CAS:528:DC%2BD1cXktFeksr4%3D 10.1016/j.cardfail.2007.11.006 18381181 This study was a randomized, double-blind, placebo-controlled trial looking at the effects of sildenafil on 19 patients with chronic HF both 1 hour and 4 weeks after chronic therapy. Patients on sildenafil therapy showed improved maximal oxygen uptake, ventilatory efficiency, oxygen uptake kinetics, and decreased pulmonary artery systolic pressures (Pubitemid 351444866)
52. M Guazzi M Samaja R Arena, et al. 2007 Long-term use of sildenafil in the therapeutic management of heart failure J Am Coll Cardiol 50 2136 2144 1:CAS:528:DC%2BD2sXhtlGiu7vM 10.1016/j.jacc.2007.07.078 18036451 (Pubitemid 350117342)
53. 2, improved 6-minute walk distance, and fewer hospitalizations for HF than patients in the placebo arm (Pubitemid 47511419)
54. D Domanski S Rosario ER Schwarz 2009 Improved erectile function after cardiac resynchronization therapy in a patient with heart failure-a case report J Sex Med 6 2910 2914 10.1111/j.1743-6109.2009.01281.x 19453907 This is a case report of a 63-year-old man with ischemic cardiomyopathy, HF, and long-standing ED who failed ED therapy with medication optimization, medication side effect adjustment, and PDE5-inhibitor therapy. The patient reported significant improvement of his ED following cardiac resynchronization therapy with placement of a biventricular implantable cardioverter-defibrillator pacemaker and no further adjustments in ED therapy
55. R Belardinelli F Lacalaprice E Faccenda, et al. 2005 Effects of short-term moderate exercise training on sexual function in male patients with chronic stable heart failure Int J Cardiol 101 83 90 10.1016/j.ijcard.2004.05. 020 15860388 (Pubitemid 40614740)
56. EE Steinke 2005 Intimacy needs and chronic illness: strategies for sexual counseling and self-management J Gerontol Nurs 31 40 50 15916202